TCM
MDGL icon

TCG Crossover Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

TCG Crossover Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-149,283
Closed -$41.8M – 38
2024
Q2 		$41.8M Hold
149,283
– – 4.36% 7
2024
Q1 		$39.9M Sell
149,283
-30,634
-17% -$7.22M 3.15% 15
2023
Q4 		$41.6M Hold
179,917
– – 4.62% 10
2023
Q3 		$26.3M Buy
179,917
+30,000
+20% +$5.65M 3.87% 14
2023
Q2 		$34.6M Hold
149,917
– – 5.68% 7
2023
Q1 		$36.3M Sell
149,917
-138,137
-48% -$37.6M 7.08% 4
2022
Q4 		$83.6M Buy
288,054
+258,054
+860% +$25.2M 14.76% 2
2022
Q3 		$1.95M Buy
+30,000
New +$2.08M 0.58% 19

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

TCG Crossover Management's MDGL Position: Q3 2024 in Review

TCG Crossover Management sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2024, closing a stake of 149,283 shares — an estimated $41.8M sold.

TCG Crossover Management first reported a position in MDGL in Q3 2022 and held it in 8 quarters. The position peaked at $83.6M in Q4 2022. 257 funds tracked by Wall St. Rank hold MDGL as of Q3 2024.

  • TCG Crossover Management reported no remaining Madrigal Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • TCG Crossover Management sold 149,283 Madrigal Pharmaceuticals shares in Q3 2024, an estimated $41.8M.
  • TCG Crossover Management first reported a position in Madrigal Pharmaceuticals in Q3 2022 and held it in 8 quarters.
  • TCG Crossover Management's Madrigal Pharmaceuticals position peaked at $83.6M in Q4 2022.
  • 257 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2024.

Based on TCG Crossover Management's 13F filing for Q3 2024, filed 14 Nov 2024.